All In Biotech

Drug Trial Radar · NCT05269316

Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination With PARP Inhibitor Senaparib in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

61

Planned (sponsor's estimate)

Start

Feb 11, 2022

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Impact Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors

Conditions

  • Solid Tumor
  • Advanced Solid Tumor

Interventions

  • IMP9064Drug

    IMP9064 Monotherapy administered for 21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (Safety and Tolerability)Time frame: 11 months
  2. To determine the Maximum Tolerable DoseTime frame: 11 months

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • Hackensack University Medical Center PARTNER

    Hackensack, New Jersey · Completed

  • Mount Sinai

    New York, New York · Completed

  • Greenville Hospital System University Medical Center (ITOR)

    Greenville, South Carolina · Completed

  • Mary Crowley Cancer Research Centers

    Dallas, Texas · Completed

  • Linear Clinical Research Limited

    Nedlands, Australia · Completed

  • Blacktown Hospital

    Blacktown, New South Wales, Australia · Completed

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.